Cationic polymers and their therapeutic potential

Purpose: Cationic polymers are widely studied as non-viral gene delivery vectors, but their therapeutic potential extends well beyond gene delivery. This review addresses the need for a broader overview of cationic polymers — their synthesis, modification, bioactive properties, architectures, and applications in drug delivery, tissue engineering, and gene therapy — while highlighting toxicity, biodegradability, and clinical translation challenges.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that cationic polymers, because of their tunable positive charge, ability to form electrostatic complexes with anionic biomolecules, and inherent bioactive properties, can serve as versatile therapeutic biomaterials for drug/gene delivery, tissue engineering, antimicrobial, antioxidant, antitumor, and anti-inflammatory applications.

Aims: Review recent advances in cationic polymers and their derivatives for gene delivery and alternative therapeutic applications. - Provide an overview of synthesis, preparation, and modification of natural and synthetic cationic polymers. - Describe inherent bioactive and intrinsic therapeutic properties of cationic polymers. - Summarize cationic polymer–based biomaterial architectures, including hydrogels, scaffolds, membranes, fibers, nanogels, micelles, nanoparticles, and dendrimers. - Highlight progress in drug delivery, tissue engineering, and gene therapy, and discuss current concerns and future research directions.

Delivery system: Polymer class: Cationic polymers bearing positive charges on the backbone and/or side chains. - Natural cationic polymers: Chitosan, cationic gelatin, cationic dextran, cationic cellulose, cationic cyclodextrin. - Synthetic cationic polymers: Poly(ethyleneimine) (PEI; linear and branched), poly(L-lysine) (PLL), poly(amidoamine) (PAA), poly(amino-co-ester) (PAE), poly(2-N,N-dimethylaminoethyl methacrylate) (PDMAEMA). - Architectures: Hydrogels, scaffolds, membranes, fibers, nanogels, micelles, nanoparticles, dendrimers. - Payloads: Plasmid DNA, siRNA, RNA, PNA, oligonucleotides, anticancer drugs (e.g., doxorubicin, paclitaxel, camptothecin, methotrexate), proteins/peptides, growth factors, vaccines, antimicrobials, nitric oxide donors. - Targeting/functional ligands: Folate, RGD peptide, transferrin, galactose, arginine/guanidine, cell-penetrating peptides, heparin-binding motifs, and others. - Stimuli-responsive features: pH, temperature, ionic strength, redox, enzymes, light, magnetic field, and multiresponsive systems.

Approach: Review of in vitro and in vivo literature, primarily covering the last decade up to 2012. In vitro models include HeLa, 293T, HepG2, COS-7, CHO, MCF-7, A549, KB, HUVEC, C2C12, PC-3, and others. In vivo models include mice, rats, guinea pigs, rabbits, and sheep, with disease contexts such as cancer, diabetes, cardiovascular disease, inflammation, and tissue regeneration. No new primary experiments, group sizes, or doses are reported.

Key methods: Synthesis/characterization: Ring-opening polymerization (ROP), ATRP, RAFT, Michael addition, click chemistry, quaternization, EDC/NHS coupling, NMR, FTIR, DLS, zeta potential, SEM/TEM, AFM. - Gene delivery: Luciferase and GFP reporter assays, siRNA-mediated gene silencing, gel electrophoresis, cellular uptake, confocal microscopy. - Drug/protein delivery: Encapsulation efficiency, release profiles, cytotoxicity assays (MTT), protein activity, insulin protection. - Bioactivity: Antimicrobial MIC assays, antioxidant/radical scavenging, antitumor efficacy, anti-inflammatory cytokine knockdown. - In vivo: Tumor growth inhibition, biodistribution, blood glucose, hair growth, tissue regeneration, biofilm reduction, biocompatibility.

Key results: Chitosan–PEI derivatives showed transfection efficiency comparable to 25 kDa PEI with significantly reduced cytotoxicity. - Heparin–PEI nanoparticles delivering mouse survivin-T34A achieved 31% transfection efficiency in C-26 cells and significantly inhibited subcutaneous C-26 carcinoma growth in vivo. - Reductively cleavable PEI–Cys conjugates enhanced in vitro transfection in HeLa and 293T cells at an N/P ratio of 10/1 under both serum and serum-free conditions. - Quaternized PEI nanoparticles incorporated into resin composites rendered more than 50% of bacteria in biofilms non-viable, including in outer biofilm regions. - PLL-grafted PEGDA hydrogels with an optimal 2 wt% PLL promoted neural progenitor cell viability, attachment, proliferation, differentiation, and neurite outgrowth. - Cationic β-cyclodextrin–insulin complexes encapsulated in alginate/chitosan nanospheres protected insulin from gastric degradation and enhanced nasal absorption.

Interpretation: Cationic polymers are highly tunable therapeutic platforms with broad utility in drug delivery, gene therapy, and tissue engineering. Biodegradable and low-toxicity derivatives — especially cationic polysaccharides and modified natural polymers — are promising for clinical translation. Continued multidisciplinary studies on structure–function relationships, endosomal escape, nuclear translocation, and biocompatibility are needed to overcome remaining barriers and realize their therapeutic potential.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Many systems remain preclinical; clinical translation is limited. - Non-degradability and toxicity of some cationic polymers remain major concerns. - Structure–function relationships are not fully established. - Studies are heterogeneous in cell lines, animal models, and endpoints, limiting direct comparison. - Long-term safety, large-animal validation, and detailed pharmacokinetics/biodistribution are not comprehensively addressed.